or Try an Advanced Search...

    Technical Analysis for NRSN - NeuroSense Therapeutics Ltd.

    Grade Last Price % Change Price Change
    D 1.20 6.96% 0.08
    NRSN closed up 6.96 percent on Wednesday, May 15, 2024, on 36 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Down
    Historical NRSN trend table...
    Date Alert Name Type % Chg
    Bollinger Band Squeeze Range Contraction 0.00%
    NR7 Range Contraction 0.00%
    NR7-2 Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    BB Squeeze Started Range Contraction 0.00%
    Inside Day Range Contraction 0.00%
    NR7 Range Contraction 6.96%
    Stochastic Reached Oversold Weakness 6.96%
    Wide Bands Range Expansion 6.96%
    Oversold Stochastic Weakness 6.96%
    Older End-of-Day Signals for NRSN ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 17 hours ago
    Possible Inside Day about 17 hours ago
    Up 5% about 21 hours ago
    Up 3% about 21 hours ago
    Up 2% about 21 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    NRSN Chart by TradingView
    Basic chart:

    Profile

    NeuroSense Therapeutics is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include ALS, Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients. Due to the complexity of neurodegenerative diseases, NeuroSense's strategy is to develop combined therapies targeting multiple pathways associated with these diseases.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biology Disease Neuroscience Alzheimer's Disease Parkinson's Disease Neurodegenerative Diseases Neurodegeneration Senescence Gladstone Institutes

    Is NRSN a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 14 NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning
    May 7 NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients
    May 2 NeuroSense Announces First Quarter 2024 Business Update
    Apr 22 NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease
    Apr 18 NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting
    Apr 12 NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024
    Apr 11 NeuroSense Therapeutics sheds 6% on $4.5M direct private offering
    Apr 10 NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement
    Apr 9 NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics
    Apr 8 NeuroSense Therapeutics GAAP EPS of -$0.83 misses by $0.01
    See more NRSN news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 2.33
    52 Week Low 0.4
    Average Volume 170,881
    200-Day Moving Average 1.06
    50-Day Moving Average 1.54
    20-Day Moving Average 1.28
    10-Day Moving Average 1.22
    Average True Range 0.17
    RSI (14) 39.76
    ADX 10.37
    +DI 17.23
    -DI 21.14
    Chandelier Exit (Long, 3 ATRs) 1.23
    Chandelier Exit (Short, 3 ATRs) 1.56
    Upper Bollinger Bands 1.47
    Lower Bollinger Band 1.09
    Percent B (%b) 0.28
    BandWidth 29.34
    MACD Line -0.11
    MACD Signal Line -0.10
    MACD Histogram -0.0032
    Fundamentals Value
    Market Cap 16.37 Million
    Num Shares 13.7 Million
    EPS -0.94
    Price-to-Earnings (P/E) Ratio -1.27
    Price-to-Sales 0.00
    Price-to-Book 4.15
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.29
    Resistance 3 (R3) 1.28 1.24 1.27
    Resistance 2 (R2) 1.24 1.22 1.24 1.27
    Resistance 1 (R1) 1.22 1.20 1.23 1.23 1.26
    Pivot Point 1.18 1.18 1.18 1.18 1.18
    Support 1 (S1) 1.16 1.16 1.17 1.17 1.13
    Support 2 (S2) 1.12 1.14 1.12 1.13
    Support 3 (S3) 1.10 1.12 1.12
    Support 4 (S4) 1.11